Recently, the checkpoint inhibitors including MDM2 antagonists and CDK4 antagonists have been shown to have some therapeutic effects in the treatment of DDLPS, and future clinical studies will help to establish novel therapeutic strategies for DDLPS. The gene discussed is MDM2; the disease is dedifferentiated liposarcoma.